Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings ⊕
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Bristol Myers Squibb
since
auto-detected in 7 stories
4 months ago
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
5 months ago
J&J's experimental psoriasis drug shows promise against Bristol's treatment ○
Johnson & Johnson said its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two head-to-head trials.
7 months ago
Trump's pharmaceutical tariffs could affect some drugmakers more than others ○
found
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
8 months ago
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug ○
Cigna accused Bristol Myers Squibb of violating antitrust law by keeping generic versions of its blood cancer drug Pomalyst off the market to retain a monopoly.
10 months ago
Trump pharma tariffs would raise U.S. drug costs by $51 billion annually, report finds ○
found
Pharmaceutical Research and Manufacturers of America includes Amgen, Bristol Myers Squibb, Eli Lilly, and Pfizer, among others.
Stocks making the biggest moves after hours: Tesla, Enphase Energy, Oklo, Bristol Myers Squibb and more ○
These are the stocks posting the largest moves in extended trading.
Stocks making the biggest moves after hours: Tesla, Enphase Energy, Oklo, Bristol Myers Squibb and more ○
These are the stocks posting the largest moves in extended trading.
page 1 of 1